Devalued and distrusted can the pharmaceutical industry restore its broken image? 9781118487471
"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Ge
322 97 1MB
English Pages 125 Year 2013;2012
Table of contents :
ACKNOWLEDGMENTS ix INTRODUCTION 1 CHAPTER 1 THE FOUR SECRETS THE DRUG COMPANIES DON T WANT YOU TO KNOW 4 Drug Companies Underestimate Dangerous Side Effects 5 Drug Companies Control Much of the Information Your Doctor Gets 10 You re Often Prescribed Drugs That You Don t Need 14 Drugs Target the Symptoms, Not the Cause 19 Conclusion 22 References 23 CHAPTER 2 WHAT HAS HAPPENED TO R&D PRODUCTIVITY? 25 Impact of Mergers on R&D Productivity 26 Heightened FDA Requirements for NDAs 34 Higher Hurdles Set by Payers 41 Conclusion 46 References 48 CHAPTER 3 KEY THERAPEUTIC AREAS FOR IMPROVING HEALTH 49 Cancer 51 Diseases of the Brain 54 Cardiovascular Disease (CVD) 60 Diabetes 63 Bacterial Infections 65 Conclusion 68 References 69 CHAPTER 4 IMPROVING R&D OUTPUT 71 The Views of Others 72 Pharma s Blockbuster Mentality Needs to Change 72 Can Predictive Innovation Lead to Greater Success Rates? 76 Would Royalties Make Scientists More Productive? 78 Will Drug Repositioning Help Fill the R&D Pipeline? 80 Consultants Don t Always Have the Facts 82 Personal Views 84 Discovery Must Focus on Productivity 85 Does Size Help or Hinder R&D Productivity? 87 To Outsource or Not to Outsource? That s the Pharma R&D Question 89 Big Pharma Early Research Collaborations 92 Conclusion 93 References 95 CHAPTER 5 RESTORING PHARMA S IMAGE 96 Illegal Detailing of Drugs 97 Pharmaceutical Companies Should Drop TV Ads 98 The Need for Greater Transparency 100 How Committed Is Big Pharma to Rare Diseases? 102 Pharmaceutical Companies and Philanthropy 104 Pharma Needs to Have Its Scientists Tell Their Stories 105 Conclusion 106 References 107 CHAPTER 6 FINAL THOUGHTS 109 References 114 INDEX 115
